This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Heraeus Precious Metals Gmbh & Co. Kg, Medac Gesellschaft Fur Klinische Spezialpraparate Mbh. Active years: 2014-2016.
Company Filing History:

Years Active: 2014-2016
Title: Andrew Lupton: Innovator in Pharmaceutical Chemistry
Introduction
Andrew Lupton is a notable inventor based in Gelnhausen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of stable crystalline forms of important compounds. With a total of 3 patents to his name, Lupton's work has the potential to impact the medical industry positively.
Latest Patents
One of Andrew Lupton's latest patents is focused on crystalline 4'-epidaunorubicin hydrochloride. This invention provides a stable and readily soluble crystalline form of the compound. The process of producing this crystalline form involves crystallizing 4'-epidaunorubicin hydrochloride in a solvent system that includes various solvents. This innovative method also outlines a way to produce an anthracycline using the crystalline form, showcasing Lupton's expertise in pharmaceutical applications.
Career Highlights
Throughout his career, Andrew Lupton has worked with prominent companies in the pharmaceutical sector. Notable among these are Heraeus Precious Metals GmbH & Co. KG and Medac Gesellschaft für Klinische Spezialpräparate mbH. His experience in these organizations has contributed to his development as a leading inventor in his field.
Collaborations
Andrew Lupton has collaborated with several professionals in his career, including Sascha Weiser and Tero Kunnari. These collaborations have likely enriched his work and contributed to his innovative approaches in pharmaceutical chemistry.
Conclusion
Andrew Lupton's contributions to the field of pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and drug formulations.